Roche's Dx Sales Increase 3 Percent in Q1 | GenomeWeb

NEW YORK (GenomeWeb News) – Roche reported today that first-quarter revenues for its diagnostics division, which includes its molecular diagnostics and applied science businesses, rose 3 percent to CHF2.36 billion ($2.06 billion) year over year.

The Swiss drugs and diagnostics giant said that its molecular diagnostics business brought in revenues of CHF294 million for the quarter with growth driven by automated real-time PCR platforms and blood-screening products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.